Soft Tissue Sarcoma Market Detailed Industry Scope, Future Market Size Scenario and Elaborates Outlook to 2023
Research Reports
Jan 22, 2021
Soft tissue sarcoma is associated with various rare cancers, which include clear cell sarcoma, angiosarcoma, alveolar soft part sarcoma, malignant mesenchymoma, adult fibrosarcoma, clear cell sarcoma, rhabdomyosarcoma, and kaposi sarcoma. Presently, there are limited treatment options available for soft tissue sarcoma
Treatment demand continues to grow for soft tissue sarcoma. The increased prevalence rate remains the major driver of the global soft tissue sarcoma market. Market Research Future (MRFR) reports that the global soft tissue sarcoma market is set to grow at 8.2% CAGR during the assessment period (2017-2023).
The R&D pipelines are expected to grow in the forthcoming years. In addition, increased focus on pacing up the approval process is likely to expand overall care and treatment quality for soft tissue sarcoma in the years to come. Sunitinib (sutent), doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and sirolimus (rapamune) are some of the pertinent drugs that are currently available.
Global Soft Tissue Sarcoma Market: Regional Segmentation
The regions covered in the report include the Middle East & Africa (MEA), Asia Pacific (APAC), Europe and the Americas. In terms of revenue, the global soft tissue sarcoma market is dominated by the Americas with North America being the brighter market. This is mainly owing to the presence of an advanced healthcare system in the region. Moreover, the rise in prevalence rate has also allowed the market to climb faster in the region. The data released by American Cancer Society, in 2016, approximately 12,390 people were suffering from soft tissue sarcoma or related cancer.
The market is also witnessing steady growth in Europe. Higher rate of incidence and favorable reimbursement policies are some of the factors that can be linked with the market growth in the region.
Request Free Sample Copy of Report with Detailed Impact Analysis of Covid-19:https://www.marketresearchfuture.com/sample_request/5304
Global Soft Tissue Sarcoma Market: Competitive Landscape
GlaxoSmithKline plc (U.K), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), and Teva Pharmaceutical Industries Ltd (Israel) are among key company discussed in the MRFR’s report.
Global Soft Tissue Sarcoma Market: Segmental Overview
The segmental analysis of the market has been conducted on the basis of disease type, treatment, end-users and distribution channel. Based on disease type, the market has been segmented into regional sarcoma, metastatic sarcoma, and local sarcoma.
Have Any Query? Connect with Our Research Expert 24*7:https://www.marketresearchfuture.com/enquiry/5304
On the basis of treatment type, the market has been segmented into radiation therapy, anti-angiogenesis drugs, targeted therapy, and chemotherapy. The radiation therapy segment is further sub-segmented into external radiation therapy and internal radiation therapy.
About Market Research Future:
Market Research Future (MRFR) is a world-renowned market research company that offers a wide range of services, complete with accurate and precise analysis about diverse markets, sub-markets and target consumers. Our approach is a combination of extensive information and multiple data sources that help provide an exhaustive comprehension about the latest major developments to the client, in addition to future events and what measures and decisions to take on the basis of the same.
Our fast emerging market research firm is armed with an adept research analysts’ team that focuses on gathering useful data and analytics in terms of economic and technological advances. Our proficient analysts conduct industrial visits in a bid to achieve reliable and accurate information from established market participants. One of our foremost objectives is to keep the client well-versed with all the lucrative opportunities as well as challenges surrounding various global markets. We offer step-by-step guidance to our clients, through consulting and strategic services, enabling them to arrive at a practical and effective decision.
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English




